
PCR Technologies Market Size, Share, Trends & Global Forecast 2026–2035
The PCR Technologies Market is Segmented By Product (Kits & Reagents, Consumables [PCR Tubes, PCR Microplates, Cap/Lids, Other Consumables], Instruments, Software & Services), By Technique (Conventional PCR, Real-time PCR, Digital PCR, Reverse Transcription PCR, Hot-start PCR, Multiplex PCR, Other Techniques), By Application (Gene Expression Analysis, Genetic Sequencing, Genotyping, Nucleic Acid Detection, Nucleic Acid Synthesis, Standard Validation/Verification, Diagnostic Application, Other Applications), By End-use (Hospitals & Diagnostic Centers, Research & Academic Institutes, Pharma & Biotech Companies, Other End-users) and Region
PCR Technologies Market Overview and Definition
The Global PCR Technologies Market was valued at USD 16.84 Billion in 2025 and is projected to reach USD 36.86 Billion by 2035, growing at a CAGR of 8.15% from 2026 to 2035. The market is driven by rising demand for molecular diagnostics, expanding genetic sequencing applications, and accelerating adoption of real-time and digital PCR technologies across clinical, research, and pharmaceutical sectors.
Real-time PCR dominates by technique, accounting for approximately 63% market share, whilst digital PCR represents the fastest-growing segment. North America leads globally with 39.5% market share, whilst Asia-Pacific records the highest regional expansion rate. Reagents and consumables generate 85.6% of market revenue, reflecting consistent demand from routine molecular testing operations. The market encompasses comprehensive PCR platforms spanning thermal cyclers, qPCR instruments, digital PCR systems, reagent kits, and integrated software solutions supporting diverse applications from infectious disease diagnostics to gene expression analysis and genomic research.
Key Market Trends & Analysis
- The Global PCR Technologies Market reached USD 16.84 billion in 2025 and is forecast to expand to USD 36.86 billion by 2035, driven by escalating demand for real-time and digital PCR methodologies in clinical diagnostics and genomic research applications.
- PCR Technologies Market is expanding at 8.15% CAGR from 2026 to 2035, with growth concentrated in digital PCR instruments and AI-enabled multiplex assay kits replacing conventional thermal cycling workflows in diagnostic laboratories.
- Global PCR Technologies Market is projected to reach USD 36.86 billion by 2035, supported by hospital implementation of automated molecular testing platforms and pharmaceutical R&D investment in high-fidelity PCR chemistries for drug development pipelines.
- Rising prevalence of infectious diseases, oncology diagnostics, and genetic disorder detection drives urgent demand for rapid real-time PCR assays and digital PCR platforms enabling absolute nucleic acid quantification in hospital microbiology laboratories worldwide.
- Real-time PCR (qPCR) techniques dominated the PCR Technologies Market in 2025 with approximately 63% market share, reflecting widespread adoption in gene expression analysis, pathogen detection, and quantitative DNA/RNA measurement across research and clinical settings.
- Reagents and consumables segment accounts for approximately 85.6% of the PCR Technologies Market in 2025, encompassing PCR tubes, microplates, caps/lids, and master mix formulations required for routine molecular amplification operations in diagnostic laboratories.
- Digital PCR instruments represent the fastest-growing PCR Technologies Market segment at approximately 11.5% CAGR, driven by absolute quantification capabilities, superior precision for copy number variation detection, and integration within next-generation genomic research workflows.
- North America captured approximately 39.5% of the Global PCR Technologies Market revenue in 2025, approximately USD 6.65 billion, supported by advanced laboratory infrastructure, substantial R&D spending, and FDA-approved diagnostic PCR assay portfolios.
- USA PCR Technologies Market reached approximately USD 4.21 billion in 2025, representing 25% of global market value, with expansion driven by hospital adoption of multiplex PCR panels for respiratory pathogen detection and clinical oncology applications.
- Asia-Pacific is the fastest-growing region in the PCR Technologies Market, expanding at approximately 10.2% CAGR through 2035, supported by diagnostic laboratory infrastructure development, rising infectious disease burden, and pharmaceutical sector PCR enzyme and kit procurement.
- Gene expression analysis application dominates the PCR Technologies Market with approximately 35% share in 2025, reflecting systematic adoption of RT-qPCR protocols in transcriptomic research, drug discovery, and biomarker validation across pharmaceutical and biotech firms.
- Hospitals and diagnostic centers account for approximately 42% of PCR Technologies Market end-user revenue in 2025, driven by routine molecular diagnostics, antimicrobial susceptibility confirmation through PCR-based resistance detection, and infectious disease surveillance protocols.
- Thermo Fisher Scientific and Bio-Rad Laboratories together control approximately 31% of the Global PCR Technologies Market through comprehensive instrument portfolios, including QuantStudio real-time systems, digital PCR platforms, and integrated assay ecosystems.
- Germany, United Kingdom, and France lead European PCR Technologies Market expansion, collectively representing 58% regional revenue, driven by clinical diagnostics investment, pharmaceutical R&D spending, and healthcare system implementation of molecular precision medicine.
The PCR Technology market provides an array of products and services that can be used to amplify and quantify nucleic acids. This includes thermal cyclers, real time/qPCR devices, digital PCR devices and PCR consumables such as PCR tubes, plates, lids and master mixes. The technologies available are conventional PCR, real time quantitative PCR, digital/droplet PCR, reverse transcription PCR, hot start polymerases and multiplexing.
Source: Kaiso Research and Consulting
The application areas for PCR technology are vast, including gene expression analysis, sequencing, genotyping, nucleic acid detection, nucleic acid production, standardisation and diagnostics. The end users include hospitals with centralised diagnostic labs, research institutions, pharma/biotech companies involved in drug discovery and quality assurance, and private diagnostic labs. The PCR Technology market also involves PCR reagents suppliers, polymerase suppliers, thermal cycler manufacturers, data analysis software and training/maintenance/assay support services.
Strategic Importance & Market Outlook
PCR Technology are strategically important in the world of molecular diagnostics and life sciences. Due to the rising prevalence of infectious diseases (including antibiotic resistant strains), it is vital to identify the pathogen quickly using PCR based diagnostic assays.
Pharma companies investing into R&D are requiring in depth gene expression analysis and copy number variant analysis using real time and digital PCR. The healthcare industry are constantly investing in precision medicine, meaning there is a constant demand for genomic testing and molecular biomarker analysis. Diagnostic Labs are investing in automation, meaning thermal cyclers and real time detection are being upgraded.
Regulations are becoming more strict meaning pathogens must be identified using molecular methods. This means PCR testing is a must for lab accreditation. Global initiatives have been put in place to help integrate the market, using standardised PCR assays. Looking ahead, the market will continue to grow due to next generation sequencing, AI data interpretation and cloud based diagnostic platforms.
In July 2025, Bio-Rad Laboratories announced launch of four new droplet digital PCR platforms including QX Continuum and QX700 series instruments, expanding its comprehensive digital PCR portfolio with over 400,000 compatible assays.
Recent Developments in the PCR Technologies Market
- In July 2025, Bio-Rad Laboratories announced the strategic launch of four new Droplet Digital PCR (ddPCR) platforms, including the QX Continuum and QX700 series instruments, significantly expanding its comprehensive digital PCR product portfolio. The expanded offering comprises over 400,000 compatible assays across research and diagnostic applications. Bio-Rad's portfolio expansion reinforces its leadership position in droplet digital PCR technology and strengthens competitive positioning in genomics research and applied science markets worldwide.
- In June 2025, Thermo Fisher Scientific announced the acquisition of Pace Biosciences to enhance its high-fidelity PCR enzyme portfolio and accelerate next-generation PCR kit development. The acquisition strengthens Thermo Fisher's capabilities in polymerase engineering and assay chemistry. Strategic acquisition of specialised PCR technology innovators enables rapid portfolio expansion and competitive differentiation in molecular diagnostics and life sciences research markets.
- In April 2026, Thermo Fisher Scientific launched the Applied Biosystems PowerFlex Thermal Cycler featuring a 10.1-inch touchscreen, AI-assisted Smart Help capabilities, and support for fully skirted microplates. The system addresses growing laboratory demand for flexible, high-throughput PCR instruments in shared research environments. Thermo Fisher's product innovation aligns with broader industry trends toward automation and multi-assay workflow optimisation in molecular biology laboratories.
- In March 2025, Roche announced a major product launch of a next-generation qPCR platform within its LightCycler portfolio, aiming to boost throughput and sensitivity for clinical diagnostics. The new platform incorporates advanced temperature control and multiplexing capabilities. Roche's LightCycler portfolio expansion strengthens competitive positioning in real-time PCR markets serving hospitals and diagnostic laboratories globally.
- In June 2026, QIAGEN announced expansion of its QIAcuity Gene Expression Assays portfolio to accelerate digital PCR adoption in research and biopharmaceutical applications. The new assays are designed to improve gene expression analysis capabilities and strengthen PCR-based molecular testing infrastructure. QIAGEN's assay expansion supports growing demand for advanced digital PCR solutions in genomic research and applied diagnostic settings.
PCR Technologies Market Dynamics: Drivers, Restraints, Opportunities, Challenges and Trends
Drivers: Rising infectious disease burden and demand for rapid molecular diagnostics propels global PCR Technologies Market expansion.
Multidrug resistant organisms, new viruses and persistent infection are increasing, therefore healthcare systems need fast diagnostic tests using PCR to detect pathogens and allow targeted antibiotic treatment. Multiplex PCR is required for monitoring respiratory pathogens.
Pharmaceutical companies are investing in genetic research, validating biomarkers and developing new drugs. Gene expression needs to be fully understood using real time PCR. Government funding has been provided into research of diseases at a genomic level and monitoring pathogens. Clinical guidelines now recommend molecular confirmation of pathogens.
Restraints: High capital equipment costs and reagent expenses limit PCR adoption in resource-constrained diagnostic settings and emerging markets.
High capital costs are required with advanced thermal cyclers, real time PCR and digital droplet PCR. This also includes laboratory space, specialist training and maintenance. High reagent costs can be a problem, especially performing high throughputs of samples. There can be numerous issues with standardisation between PCR machines and PCR chemistry.
There is also a risk with reagent supply chains which can cause problems with the availability of key ingredients like polymerases, probes and fluorescent dyes. Lastly, there are issues with skilled staff as PCR assay design requires skilled individuals which can be an issue in areas where there is a lack of skilled lab staff.
Opportunities: Emerging markets in Asia-Pacific and Latin America present significant PCR Technologies Market expansion opportunities through diagnostic infrastructure development.
An increase in diagnostics lab infrastructure in India, China and Southeast Asia there is significant demand for Thermal Cyclers, qPCR instruments and reagents. Growth in pharmaceutical manufacturing in emerging markets also leads to internal demand for PCR based QC and release testing. Additionally, Point of care PCR platforms are being developed to increase accessibility. The integration of AI and machine learning into PCR data analysis increases diagnostic accuracy and reduces variation between assays. Digital health and cloud based PCR surveillance provides real time information on pathogen resistance and helps understand trends in epidemiology.
Challenges: Integration of next-generation sequencing with conventional PCR workflows creates technical and workflow complexity in established laboratory environments.
It can be difficult to compare results across different PCR, detection technology and software platforms. This can make it challenging to make comparisons and ensure consistency in multi centre diagnostic networks. New PCR assay formats and detection chemistries need to be validated, increasing development to implementation timescales and requiring significant clinical data generation.
Competition from cheaper manual PCR platforms can reduce the profitability of more expensive automated and digital platforms. Disruptions to the supply chain can also cause issues with obtaining key reagents. Training requirements for new PCR technologies can also be an issue for labs with limited technical resources.
Trends: Shift toward multiplex and digital PCR technologies is transforming diagnostic capabilities and enabling absolute nucleic acid quantification.
Digital PCR systems have been gaining traction in the clinical setting with their ability to perform absolute quantification of nucleic acids without the need for external standards. The multiplexing capabilities of these PCR systems enable detection of multiple respiratory, gastrointestinal and antimicrobial resistance markers, to meet the needs of a hospital setting to provide a rapid diagnosis for a syndrome.
Integration of artificial intelligence into the thermal cycler enables an optimised assay design, analysis of cycle threshold in real time and predictive interpretation. PCR machines with cloud connectivity provide remote monitoring of the instrument. High throughput thermal cyclers with automated sample handling increase efficiency in the lab.
Where Are the Biggest Opportunities in the PCR Technologies Market?
- Multiplex PCR assay expansion simultaneously detecting respiratory, gastrointestinal, and sexually transmitted pathogens addresses clinical demand for rapid syndromic diagnosis in emergency departments and acute care settings.
- Point-of-care PCR platform development targeting decentralised testing environments expands market addressability beyond centralised laboratory settings, particularly in resource-limited and rural diagnostic locations.
- Artificial intelligence-enabled PCR data interpretation systems reducing inter-assay variability and automating result analysis create significant competitive differentiation opportunity for software and platform developers.
- Next-generation sequencing integration with targeted PCR amplification creates hybrid molecular testing platforms addressing whole-genome analysis demands in pharmacogenomics and tumour mutation profiling applications.
- Digital PCR adoption acceleration in biopharmaceutical manufacturing supports viral vector titration, gene therapy product quality control, and companion diagnostic development for personalised medicine applications.
- Asia-Pacific diagnostic laboratory infrastructure development and pharmaceutical manufacturing expansion create substantial demand for thermal cyclers, qPCR instruments, and reagent supplies.
- Cloud-based PCR data management and real-time surveillance platform development enable epidemiological monitoring and antimicrobial resistance trend analysis supporting public health initiatives.
- Rapid PCR technology development targeting 15–30 minute amplification cycles addresses acute care diagnostic demands in emergency departments, operating theatres, and point-of-care settings.
- Copy number variation detection through digital PCR supports cancer genomics research, prenatal diagnostics, and pharmacogenomic testing applications in precision medicine frameworks.
- Sustainable PCR chemistry development reducing reagent consumption, minimising waste generation, and lowering environmental footprint appeals to healthcare systems prioritising operational sustainability.
PCR Technologies Market Segmentation Analysis
Report Attributes | Details |
Market Size in 2025 | USD 16.84 Billion |
Market Size by 2035 | USD 36.86 Billion |
CAGR (2026-2035) | 8.15% |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Historical Data | 2022-2024 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook |
Key Segments | By Product:
By Technique: Conventional PCR, Real-time PCR, Digital PCR, Reverse Transcription PCR, Hot-start PCR, Multiplex PCR, Other Techniques By Application: Gene Expression Analysis, Genetic Sequencing, Genotyping, Nucleic Acid Detection, Nucleic Acid Synthesis, Standard Validation/Verification, Diagnostic Application, Other Applications By End-use: Hospitals & Diagnostic Centers, Research & Academic Institutes, Pharma & Biotech Companies, Other End-users |
Regional Analysis/Coverage | North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia, Africa, Rest of Latin America) |
Company Profiles | Abbott Laboratories, Agilent Technologies Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Danaher Corporation, Eppendorf SE, F. Hoffmann-La Roche Ltd., Illumina Inc., Merck KGaA, New England Biolabs, Promega Corporation, QIAGEN N.V., Standard Biotools Inc., Takara Holdings Inc., Thermo Fisher Scientific Inc. |
Source: Kaiso Research and Consulting
PCR Technologies Market Segment Analysis
- By Technique, Real-time PCR dominated the PCR Technologies Market in 2025 with approximately 63% share; Digital PCR is the fastest-growing technique with approximately 11.5% CAGR from 2026 to 2035.
- By Product, Reagents & Consumables dominated the PCR Technologies Market in 2025 with approximately 85.6% share; Instruments segment is the fastest-growing product category with approximately 10.8% CAGR.
- By Application, Gene Expression Analysis dominated the PCR Technologies Market in 2025 with approximately 35% share; Genetic Sequencing represents the fastest-growing application with approximately 9.5% CAGR.
- By End-use, Hospitals & Diagnostic Centers accounted for approximately 42% market share in 2025; Research & Academic Institutes represent the fastest-growing end-user segment with approximately 9.2% CAGR.
Dominating Segments in the PCR Technologies Market
By Technique: Real-time PCR maintains dominance through clinical validation whilst digital PCR drives fastest market growth.
The Real-Time PCR (qPCR) segment dominated the market in 2025 with a market share of around 63%. This is due to there being a large amount of clinical validation of real-time PCR for infectious disease diagnosis, gene expression and quantification of DNA/RNA. Real-time PCR offers well-established protocols for assays, standard interpretation of results and widely available reagents from various companies. It is also a cost-effective technique compared to digital PCR so is still used in high-throughput diagnostic labs. Real-time PCR is also well integrated into hospital lab systems and has been validated by regulatory bodies.
The Digital PCR technique is the fastest growing technique with a CAGR of around 11.5% between now and 2035. This is because digital PCR provides highly accurate quantification data, allowing absolute quantification without the need for calibration. It can divide samples into thousands of individual reactions which allows for rare mutations to be detected at low levels. This makes it useful for precision medicine such as oncology, prenatal testing and pharmacogenomics. New applications are arising using digital PCR such as circulating tumour-DNA and viral load quantification in immunocompromised patients which is driving usage in diagnostic labs.
In June 2026, QIAGEN announced QIAcuity Gene Expression Assays expansion, enabling digital PCR adoption acceleration in research and biopharmaceutical development applications across Europe and North America.
By Product: Reagents & Consumables dominate through recurring purchasing whilst Instruments segment records fastest growth trajectory.
Reagents and consumables accounted for around 85.6% of the PCR Technologies Market in 2025. This includes PCR tubes, microplates, lids/caps, master mixes and assay kits. The regular demand for consumables from high volume diagnostic labs means that this market has a steady revenue stream. As they are relatively low cost compared to instruments, this is an appealing revenue source for manufacturers. They also have standardised consumables to fit with different thermal cyclers.
The instrument category is seeing the most growth within the market at around 10.8% CAGR through to 2035. This is due to hospitals investing in real time and digital PCR machines. Due to the capital expenditure on purchasing these types of instruments, and as labs are becoming more automated this category is seeing increased growth. Software and services are a new revenue stream increasing in value as more labs are connecting to the cloud and using Artificial Intelligence to analyse their data. Instrument manufacturers can differentiate themselves by being compatible with laboratory information systems.
In April 2026, Thermo Fisher Scientific launched PowerFlex Thermal Cycler featuring AI-assisted Smart Help and advanced temperature control supporting multi-assay workflow optimisation in research and diagnostic laboratories.
By Application: Gene Expression Analysis dominates through research demand whilst Genetic Sequencing drives fastest application growth.
In 2025 Gene Expression Analysis had the highest market share in the PCR Technologies Market at 35%. This is due to the popularity of research into this field. Real time PCR for mRNA quantification is a gold standard method used in functional genomics research. Academic institutions and research centres have full qPCR capabilities. The pharmaceutical industry uses gene expression analysis to discover new biomarkers for the development of precision medicine programmes.
The fastest growing application segment is Genetic Sequencing which has been growing at 9.5% CAGR up until 2035. Next generation sequencing combined with targeted PCR means there are now hybrid methods available to sequence the whole genome. Targeted amplicon sequencing using PCR enables the sequencing of specific regions of DNA. There are new technologies emerging in the market such as liquid biopsy and cell free DNA. Targeted PCR methodologies can be used to increase the amount of low abundance variants before sequencing. Copy number variation can also be detected using PCR based techniques for cancer genomics and prenatal diagnostics.
In June 2025, Thermo Fisher Scientific acquired Pace Biosciences, strengthening high-fidelity PCR enzyme portfolio supporting next-generation sequencing library preparation and targeted amplification applications.
By End-use: Hospitals & Diagnostic Centers dominate end-user demand whilst Research Institutes drive fastest growth.
Hospitals & Diagnostic Centers accounted for around 42% of the PCR Technologies Market in 2025. Hospital centralized microbiology labs perform routine PCR testing for infectious diseases, antimicrobial resistance and molecular microbiology. These labs are heavily reliant on having a steady supply of PCR products to process high volumes of samples every day. Emergency departments and ICU have seen an increase in fast multiplex PCR testing to allow quick diagnosis at point of care. Reference labs also provide specialist testing to identify complex organisms and confirm resistance mechanisms to aid antimicrobial stewardship programs within the institution.
Research & Academia is the fastest growing sector of the end user market with an estimated CAGR of 9.2% over the forecast period. University and research institutes are increasing their genomic research, gene expression and validation projects. Pharmaceutical and bio-tech companies are using PCR products and enzymes in high volumes for drug discovery and quality assurance. Research institutes often collaborate with pharmaceutical companies which requires them to have advanced PCR technologies. Government funded genomic research projects are also driving high demand for PCR consumables and reagents.
In July 2025, Abbott Laboratories announced strategic collaboration with Takara Bio to co-develop PCR-based infectious disease diagnostics, combining clinical testing capabilities with advanced PCR chemistry expertise.
Regional Insights in the PCR Technologies Market
Regional Analysis Table
Region | Major Country | Share within Region, 2025 (%) |
North America | USA | 63.3 |
Europe | Germany | 32.8 |
Asia Pacific | China | 48.5 |
Latin America | Brazil | 42.1 |
North America: Advanced laboratory infrastructure and biotechnology research spending position North America as market leader.
North America has continued to capture a significant amount of the global PCR Technologies Market with revenues totaling just under USD 6.65 billion in 2025 (39.5%). This is due to the mature diagnostic laboratory industry and large investment into pharmaceutical research and development. This region will grow at an average rate of 6.8% up until 2035. With hospitals using multiplex PCR tests to detect respiratory pathogens and confirm antibiotic resistance, there is constant demand for PCR diagnostic testing. Many pharmaceutical companies are located within North America and therefore have large investment into PCR.
Government funding has gone into researching diseases using genomics, meaning investment has been made in PCR diagnostic testing facilities. The academic research sector have advanced molecular biology laboratories that require complete PCR technologies. With a focus on precision medicine within healthcare, there is constant demand for these next generation PCR technologies.
In April 2026, Thermo Fisher Scientific launched the PowerFlex Thermal Cycler in North American laboratories, featuring AI-assisted functionality and multi-assay workflow optimisation capabilities for clinical diagnostics.
USA: Clinical diagnostic demand and biotechnology R&D investment drive sustained market expansion in PCR Technologies.
The market size for the United States PCR Technologies was estimated at USD 4.21 Billion in 2025 and is expected to grow to USD 5.84 Billion by 2035, growing at a CAGR of 3.4% between 2026 and 2035. This accounts for around 25.0% of the overall market value due to advanced diagnostic infrastructures and extensive use of PCR technologies in hospitals, diagnostic labs and research centres. The United States accounts for around 63.3% of the North American market.
Within clinical laboratories there is high demand for PCR technologies as a result of increased prevalence of infectious diseases, monitoring of antimicrobial resistance in hospitals and routine implementation of rapid multiplex PCR tests within emergency departments and acute care. Reference labs offer advanced PCR services such as copy number variation and single gene mutation detection for genetic conditions.
Pharmaceutical companies involved in drug discovery and development will use PCR extensively for target validation, gene expression and biomarker detection. Government agencies such as CDC and NIH support antimicrobial resistance monitoring and genomic research into diseases. This leads to funding being provided for upgrading diagnostic laboratories. Reimbursement is also provided via clinical laboratory improvement amendments.
In June 2025, Thermo Fisher Scientific acquired Pace Biosciences to strengthen high-fidelity PCR enzyme development capabilities supporting pharmaceutical R&D and clinical diagnostic applications across USA healthcare systems.
Europe: Government antimicrobial resistance programmes and healthcare system modernisation drive diagnostic PCR demand.
Approximately 17.4% of revenue is generated from PCR Technologies Market in Europe. This is expected to grow at a CAGR of around 7.2% till 2035. The market is growing in Europe as countries like Germany, UK, France, and others have national action plans against antimicrobial resistance. These require infrastructure for molecular diagnosis and susceptibility testing.
The market is growing due to hospital and laboratory consolidation. This provides an opportunity for companies to provide complete diagnostic platforms and reagents to multiple facilities. Germany, United Kingdom and France account for around 58% of the European market. These countries have highly developed diagnostic laboratories and spend large amounts on healthcare.
PCR assays are being implemented in a structured way due to regulations in Europe. For example, EUCAST guidelines for antimicrobial susceptibility testing. Research hubs in pharmaceuticals are concentrated in Europe, providing cutting edge PCR technologies to support drug discovery and pre-clinical development. Pressure in healthcare to make systems more efficient means automation is being adopted in high volume diagnostic centres.
In March 2025, Roche announced next-generation qPCR platform launch within its LightCycler portfolio, addressing European diagnostic laboratory demands for improved throughput and clinical sensitivity in molecular pathogen detection.
Asia-Pacific: Diagnostic laboratory infrastructure expansion and rising pharmaceutical sector PCR demand drive fastest regional growth.
The Asia-Pacific region is forecast to grow fastest at ~10.2% CAGR between now and 2035 due to modernisation of healthcare systems, increased investment in diagnostic laboratories and increased awareness of molecular precision medicine. The Asia-Pacific region will have a significant market share (20-22%) based on available data. China will be the largest country within the region.
The growth in healthcare spending seen in developing and middle income countries has led to increased investment in diagnostic instrumentation and reagents. Growth in the pharmaceutical and biotech sectors also means increased demand for PCR services. In addition, government antimicrobial resistance surveillance programs are driving demand for systematic testing.
The consolidation of hospital and diagnostic laboratories provides an opportunity for diagnostic instrumentation and reagent companies. Training and skills development programs can be used to provide local diagnostic expertise. Opportunities include entering new healthcare markets by providing diagnostic instrumentation; as well as developing affordable PCR instrumentation for laboratories which may have limited resources.
In June 2026, QIAGEN announced QIAcuity Gene Expression Assays portfolio expansion, enabling digital PCR adoption acceleration in Asia-Pacific research institutions and biopharmaceutical development applications.
Japan: Advanced diagnostictechnology adoption and precision medicine initiatives position Japan as regional innovation leader.
Japan holds a large share of the Asia-Pacific market (14-16%) and is growing at a strong CAGR rate of about 7.8% up to 2035. The market is characterised by well-developed healthcare systems and a high adoption of lab technologies. Integrated real-time and digital PCR devices are being used in hospital labs. Government anti-microbial resistance monitoring programs are encouraging the use of PCR methods.
The concentrated pharmaceutical research sector, and government guidelines requiring comprehensive gene expression analysis, are also driving significant demand for PCR reagents and enzymes. A focus on accurate diagnostics within the healthcare system is also driving adoption of automation. Automation is encouraged from integration with lab information systems and digital health. There are also issues with staffing within the healthcare industry, driving automation to increase efficiency. Opportunities exist to develop ultra-fast PCR methods and AI-based interpretation systems.
In July 2025, Bio-Rad Laboratories announced Droplet Digital PCR platform expansion addressing Japan’s genomics research and diagnostic laboratory demands for absolute nucleic acid quantification capabilities.
LAMEA: Emerging market healthcare infrastructure development and diagnostic laboratory capacity building drive expanding demand.
LAMEA represents approximately 7–9% of global PCR Technologies Market revenue based on available estimates, expanding at approximately 8.6% CAGR through 2035, reflecting diagnostic laboratory infrastructure development and rising healthcare spending in middle-income countries. Regional market growth is concentrated in Brazil, Mexico, Argentina, and select locations with expanding healthcare systems and research infrastructure.
Healthcare system modernisation initiatives support investment in diagnostic laboratory equipment and consumable procurement. Government antimicrobial resistance surveillance programmes generate sustained testing demand. Diagnostic laboratory consolidation and independent laboratory networks create opportunity for equipment vendors and reagent suppliers.
Healthcare workforce development and training programme expansion establish local diagnostic expertise supporting laboratory capability. Point-of-care and manual PCR methodologies gain adoption in resource-constrained settings. Regulatory framework development and clinical guideline harmonisation support methodology standardisation across regional healthcare systems.
In June 2026, Abbott Laboratories and Takara Bio announced strategic PCR diagnostics collaboration targeting Latin America and developing-market infectious disease diagnostic demands and healthcare infrastructure.
How Can Stakeholders Benefit from the PCR Technologies Market Report?
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.

